FY2026 Earnings Estimate for IONS Issued By Leerink Partnrs

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) – Equities researchers at Leerink Partnrs cut their FY2026 EPS estimates for Ionis Pharmaceuticals in a research note issued to investors on Monday, February 24th. Leerink Partnrs analyst M. Foroohar now anticipates that the company will post earnings of ($3.25) per share for the year, down from their prior forecast of ($3.24). The consensus estimate for Ionis Pharmaceuticals’ current full-year earnings is ($3.50) per share. Leerink Partnrs also issued estimates for Ionis Pharmaceuticals’ FY2027 earnings at ($1.62) EPS.

Ionis Pharmaceuticals (NASDAQ:IONS) last issued its earnings results on Wednesday, February 19th. The company reported ($0.66) earnings per share for the quarter, beating the consensus estimate of ($1.12) by $0.46. Ionis Pharmaceuticals had a negative net margin of 64.25% and a negative return on equity of 100.05%. The business had revenue of $227.00 million for the quarter, compared to analyst estimates of $140.97 million. During the same period in the previous year, the business earned $0.12 EPS. The firm’s revenue was down 30.2% on a year-over-year basis.

Several other brokerages have also commented on IONS. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $70.00 price target on shares of Ionis Pharmaceuticals in a research note on Thursday, February 20th. William Blair restated an “outperform” rating on shares of Ionis Pharmaceuticals in a research note on Friday, December 20th. Wells Fargo & Company dropped their target price on shares of Ionis Pharmaceuticals from $82.00 to $77.00 and set an “overweight” rating for the company in a research report on Thursday, November 7th. Citigroup cut their price target on shares of Ionis Pharmaceuticals from $67.00 to $64.00 and set a “buy” rating for the company in a report on Thursday, February 20th. Finally, BMO Capital Markets decreased their price objective on shares of Ionis Pharmaceuticals from $60.00 to $45.00 and set a “market perform” rating on the stock in a research note on Thursday, February 20th. Two analysts have rated the stock with a sell rating, five have assigned a hold rating, thirteen have issued a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $60.00.

Ionis Pharmaceuticals Stock Up 5.9 %

NASDAQ IONS opened at $33.19 on Thursday. Ionis Pharmaceuticals has a 1-year low of $30.23 and a 1-year high of $52.34. The company has a market capitalization of $5.28 billion, a price-to-earnings ratio of -10.92 and a beta of 0.34. The stock’s 50 day moving average is $33.23 and its two-hundred day moving average is $37.94. The company has a current ratio of 8.47, a quick ratio of 8.82 and a debt-to-equity ratio of 2.12.

Insiders Place Their Bets

In related news, EVP Patrick R. O’neil sold 1,207 shares of the business’s stock in a transaction that occurred on Thursday, February 20th. The shares were sold at an average price of $32.35, for a total transaction of $39,046.45. Following the completion of the sale, the executive vice president now directly owns 56,245 shares of the company’s stock, valued at $1,819,525.75. The trade was a 2.10 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, CEO Brett P. Monia sold 33,445 shares of the stock in a transaction that occurred on Thursday, January 16th. The shares were sold at an average price of $32.63, for a total transaction of $1,091,310.35. Following the completion of the transaction, the chief executive officer now owns 207,396 shares in the company, valued at $6,767,331.48. This represents a 13.89 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 111,816 shares of company stock valued at $3,603,914. 2.71% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Ionis Pharmaceuticals

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Capital World Investors grew its position in shares of Ionis Pharmaceuticals by 46.5% during the 4th quarter. Capital World Investors now owns 11,465,413 shares of the company’s stock worth $400,831,000 after buying an additional 3,637,041 shares during the period. Norges Bank bought a new position in Ionis Pharmaceuticals during the 4th quarter worth approximately $59,948,000. Vanguard Group Inc. grew its holdings in Ionis Pharmaceuticals by 9.4% during the fourth quarter. Vanguard Group Inc. now owns 16,472,539 shares of the company’s stock valued at $575,880,000 after purchasing an additional 1,416,781 shares during the period. Vestal Point Capital LP bought a new stake in Ionis Pharmaceuticals in the fourth quarter valued at approximately $20,801,000. Finally, Orbimed Advisors LLC raised its holdings in Ionis Pharmaceuticals by 21.2% in the fourth quarter. Orbimed Advisors LLC now owns 2,817,347 shares of the company’s stock worth $98,494,000 after purchasing an additional 492,900 shares during the period. Institutional investors own 93.86% of the company’s stock.

Ionis Pharmaceuticals Company Profile

Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy.